Gerard M McGeehan
Overview
Explore the profile of Gerard M McGeehan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
775
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bourgeois W, Cutler J, Aubrey B, Wenge D, Perner F, Martucci C, et al.
Blood
. 2023 Dec;
143(15):1513-1527.
PMID: 38096371
Small molecules that target the menin-KMT2A protein-protein interaction (menin inhibitors) have recently entered clinical trials in lysine methyltransferase 2A (KMT2A or MLL1)-rearranged (KMT2A-r) and nucleophosmin-mutant (NPM1c) acute myeloid leukemia (AML)...
2.
Fiskus W, Mill C, Birdwell C, Davis J, Das K, Boettcher S, et al.
Blood Cancer J
. 2023 Apr;
13(1):53.
PMID: 37055414
Monotherapy with Menin inhibitor (MI), e.g., SNDX-5613, induces clinical remissions in patients with relapsed/refractory AML harboring MLL1-r or mtNPM1, but most patients either fail to respond or eventually relapse. Utilizing...
3.
Mill C, Fiskus W, Das K, Davis J, Birdwell C, Kadia T, et al.
Leukemia
. 2023 Mar;
37(6):1336-1348.
PMID: 36977823
In AML with NPM1 mutation causing cytoplasmic dislocation of NPM1, treatments with Menin inhibitor (MI) and standard AML chemotherapy yield complete remissions. However, the causal and mechanistic linkage of mtNPM1...
4.
Issa G, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, et al.
Nature
. 2023 Mar;
615(7954):920-924.
PMID: 36922593
Targeting critical epigenetic regulators reverses aberrant transcription in cancer, thereby restoring normal tissue function. The interaction of menin with lysine methyltransferase 2A (KMT2A), an epigenetic regulator, is a dependence in...
5.
Perner F, Stein E, Wenge D, Singh S, Kim J, Apazidis A, et al.
Nature
. 2023 Mar;
615(7954):913-919.
PMID: 36922589
Chromatin-binding proteins are critical regulators of cell state in haematopoiesis. Acute leukaemias driven by rearrangement of the mixed lineage leukaemia 1 gene (KMT2Ar) or mutation of the nucleophosmin gene (NPM1)...
6.
Carter B, Mak P, Tao W, Ostermann L, Mak D, Ke B, et al.
Haematologica
. 2023 Feb;
108(9):2513-2519.
PMID: 36727398
No abstract available.
7.
Sparbier C, Gillespie A, Gomez J, Kumari N, Motazedian A, Chan K, et al.
Nat Cell Biol
. 2023 Jan;
25(2):258-272.
PMID: 36635503
Precise control of activating H3K4me3 and repressive H3K27me3 histone modifications at bivalent promoters is essential for normal development and frequently corrupted in cancer. By coupling a cell surface readout of...
8.
Aubrey B, Cutler J, Bourgeois W, Donovan K, Gu S, Hatton C, et al.
Nat Cancer
. 2022 May;
3(5):595-613.
PMID: 35534777
Acute myeloid leukemia (AML) remains difficult to treat and requires new therapeutic approaches. Potent inhibitors of the chromatin-associated protein MENIN have recently entered human clinical trials, opening new therapeutic opportunities...
9.
Fiskus W, Boettcher S, Daver N, Mill C, Sasaki K, Birdwell C, et al.
Blood Cancer J
. 2022 Jan;
12(1):5.
PMID: 35017466
Treatment with Menin inhibitor (MI) disrupts the interaction between Menin and MLL1 or MLL1-fusion protein (FP), inhibits HOXA9/MEIS1, induces differentiation and loss of survival of AML harboring MLL1 re-arrangement (r)...
10.
Heikamp E, Henrich J, Perner F, Wong E, Hatton C, Wen Y, et al.
Blood
. 2021 Sep;
139(6):894-906.
PMID: 34582559
Translocations involving the NUP98 gene produce NUP98-fusion proteins and are associated with a poor prognosis in acute myeloid leukemia (AML). MLL1 is a molecular dependency in NUP98-fusion leukemia, and therefore...